Interesting, and makes sense. Notably, seizure alleviation was not made a primary outcome. The company just appears to be hoping 2-73 has some ancillary effect worth testing for. It may or may not, we'll see.
We've done pre-clinical work on epilepsy models and had hopeful signs. But Rett is not epilepsy.
Market Data 
Markets 
AI
